Estimates of the direct medical costs attributable to human papillomavirus (HPV) can help to
quantify the economic burden of HPV and to illustrate the potential benefits of HPV …

INTRODUCTION: The objective of this study was to estimate the cost-effectiveness of adding
human papillomavirus (HPV) vaccination of 12-year-old males to a female-only vaccination …

The anogenital human papillomavirus (HPV) is estimated to be the most commonly
occurring sexually transmitted infection in the US. Comprehensive estimates of the annual …

We describe a simplified model, based on the current economic and health effects of human
papillomavirus (HPV), to estimate the cost-effectiveness of HPV vaccination of 12-year-old …

BY ANY MEASURE, GENITAL HUMAN PAPILLOMAVIRUS (HPV) infection and HPV-
associated cervical can-cer are significant national and global public health concerns. An …

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor
for cervical cancer. Given the substantial disease and death associated with HPV and …

OBJECTIVE: The purpose of this study was (1) to estimate the direct medical costs of 7 major
noncervical human papillomavirus (HPV)–related conditions that include genital cancers …

OBJECTIVE: The purpose of this study was to examine the health care costs of cervical
human papillomavirus–related disease in a US health care setting. STUDY DESIGN: We …

Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

AIM: Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be
effective against infection and disease. We examined whether HPV vaccination has the …